Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, General Counsel | April 01, 2021 | April 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date April 01, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,388 |
Ending reported balance
After 2021-04-01 transaction · row 25
25 source rows · reconciled sequenceRow 1 · 2021-04-01 · Exercise / conversion · Acquired 33,000 · Balance 148,842 Row 2 · 2021-04-01 · Sale · Disposed 2,010 · Balance 146,832 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 3 · 2021-04-01 · Sale · Disposed 8,266 · Balance 138,566 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 4 · 2021-04-01 · Sale · Disposed 3,233 · Balance 135,333 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 5 · 2021-04-01 · Sale · Disposed 3,234 · Balance 132,099 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 6 · 2021-04-01 · Sale · Disposed 1,067 · Balance 131,032 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 7 · 2021-04-01 · Exercise / conversion · Acquired 21,000 · Balance 152,032 Row 8 · 2021-04-01 · Sale · Disposed 1,256 · Balance 150,776 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 9 · 2021-04-01 · Sale · Disposed 4,818 · Balance 145,958 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 10 · 2021-04-01 · Sale · Disposed 2,728 · Balance 143,230 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 11 · 2021-04-01 · Sale · Disposed 1,724 · Balance 141,506 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 12 · 2021-04-01 · Sale · Disposed 963 · Balance 140,543 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 13 · 2021-04-01 · Exercise / conversion · Acquired 10,000 · Balance 150,543 Row 14 · 2021-04-01 · Sale · Disposed 700 · Balance 149,843 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 15 · 2021-04-01 · Sale · Disposed 2,644 · Balance 147,199 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 16 · 2021-04-01 · Sale · Disposed 951 · Balance 146,248 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 17 · 2021-04-01 · Sale · Disposed 1,049 · Balance 145,199 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 18 · 2021-04-01 · Sale · Disposed 123 · Balance 145,076 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Row 19 · 2021-04-01 · Exercise / conversion · Acquired 33,001 · Balance 178,077 Row 20 · 2021-04-01 · Sale · Disposed 1,965 · Balance 176,112 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 21 · 2021-04-01 · Sale · Disposed 6,768 · Balance 169,344 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 22 · 2021-04-01 · Sale · Disposed 3,361 · Balance 165,983 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 23 · 2021-04-01 · Sale · Disposed 2,258 · Balance 163,725 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 24 · 2021-04-01 · Sale · Disposed 1,213 · Balance 162,512 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 25 · 2021-04-01 · Sale · Disposed 124 · Balance 162,388 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2027-01-05 | Direct | 39,000 |
Reported balance
After 2021-04-01 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2021-04-01 · Exercise / conversion · Disposed 33,000 · Balance 39,000 F22: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2027-12-11 | Direct | 29,090 |
Reported balance
After 2021-04-01 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2021-04-01 · Exercise / conversion · Disposed 21,000 · Balance 29,090 F23: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.58 · Expires 2028-12-17 | Direct | 51,000 |
Reported balance
After 2021-04-01 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2021-04-01 · Exercise / conversion · Disposed 10,000 · Balance 51,000 F24: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.83 · Expires 2026-02-02 | Direct | 6,116 |
Reported balance
After 2021-04-01 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2021-04-01 · Exercise / conversion · Disposed 33,001 · Balance 6,116 F25: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 262,210 |
Reported balance
Holding disclosure · report date 2021-04-01 · row 26
Holding and transaction disclosures are not merged.
1 source rowRow 26 · Balance 262,210 F21: Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F21: Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares.
F22: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021.
F23: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021.
F24: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021.
F25: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 33,001 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · derivative · entry 30 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,116 Underlying: Common Stock · 33,001 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F25 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · derivative · entry 29 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 10,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · derivative · entry 28 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,090 Underlying: Common Stock · 21,000 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F23 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · derivative · entry 27 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 33,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 124 | $85.76 | $10,634.24 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 25 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,388 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,213 | $84.73 | $102,777.49 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 24 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,512 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,258 | $83.85 | $189,333.30 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 23 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,725 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,361 | $82.77 | $278,189.97 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 22 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,983 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,768 | $81.87 | $554,096.16 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 21 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,344 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,965 | $80.85 | $158,870.25 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 20 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,112 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 33,001 | $6.83 | $225,396.83 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 19 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 123 | $85.14 | $10,472.22 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 18 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,076 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,049 | $83.98 | $88,095.02 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 17 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,199 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 951 | $82.87 | $78,809.37 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 16 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,248 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,644 | $81.95 | $216,675.80 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 15 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,199 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 700 | $80.73 | $56,511.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 14 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,843 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $14.58 | $145,800.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 13 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 963 | $84.87 | $81,729.81 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 12 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,543 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,724 | $83.72 | $144,333.28 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 11 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,506 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,728 | $82.63 | $225,414.64 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 10 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,230 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,818 | $81.83 | $394,256.94 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 9 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,958 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,256 | $80.82 | $101,509.92 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 8 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,776 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 21,000 | $18.30 | $384,300.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 7 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,067 | $84.94 | $90,630.98 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 6 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,032 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,234 | $83.91 | $271,364.94 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,099 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,233 | $82.76 | $267,563.08 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,333 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,266 | $81.89 | $676,902.74 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,566 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,010 | $80.79 | $162,387.90 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,832 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 33,000 | $13.88 | $458,040.00 |
DisclosureSEC source: 0001209191-21-024888 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 17:52 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018324 · doc4.xml · derivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires not disclosed F2 · derivative.exercise_price: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 17:52 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 73,500 | $0.00 Strike: $57.71 | $0.00 |
DisclosureSEC source: 0001209191-21-018324 · doc4.xml · derivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 73,500 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 3, 2021 with respect to 73,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-009085 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,090 Underlying: Common Stock · 21,000 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 54,475 shares as of February 9, 2021. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 11,489 | $75.00 | $861,675.00 |
DisclosureSEC source: 0001209191-21-009085 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,920 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 21,000 | $18.30 | $384,195.00 |
DisclosureSEC source: 0001209191-21-009085 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · derivative · entry 16 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 10,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 36,979 shares as of February 1, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · derivative · entry 15 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 33,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · derivative · entry 14 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,117 Underlying: Common Stock · 66,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 755 | $65.07 | $49,127.85 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 12 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,409 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.94 to $65.34, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,386 | $64.18 | $153,133.48 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 11 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,164 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.83 to $64.795, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,326 | $63.44 | $147,561.44 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 10 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,550 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.81 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $14.58 | $145,800.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 9 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,827 | $65.05 | $183,896.35 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 8 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,876 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.56, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,366 | $64.16 | $536,762.56 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 7 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,703 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.72, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,617 | $63.34 | $419,120.78 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 6 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,069 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.74 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 33,000 | $13.88 | $458,040.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,312 | $65.01 | $345,333.12 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,686 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.72 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 15,594 | $64.11 | $999,731.34 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,998 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 10,476 | $63.31 | $663,235.56 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,592 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.685, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 66,000 | $6.83 | $450,780.00 |
DisclosureSEC source: 0001209191-21-007637 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 20:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,078 | $55.86 | $116,077.08 |
DisclosureSEC source: 0001209191-21-001712 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,990 F2 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of 4,792 performance-based restricted stock units ("PRSUs") on December 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.